MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$2,030,765
EPS
-$0.33
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
Research and development costs
50,696
General and administrative costs
1,750,658
Total costs and expenses
1,801,354
Loss from operations
-1,801,354
Interest income
4,430
Interest expense
457
Unrealized gain (loss) on digital assets
-182,887
Realized gain (loss) on foreign currency transactions
-130
Net loss
-1,980,398
Series b convertible preferred stock 8 cumulative dividend
-50,367
Net loss attributable to common stockholders
-2,030,765
Basic EPS
-0.33
Diluted EPS
-0.33
Basic Average Shares
6,171,195
Diluted Average Shares
6,171,195
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net loss
attributable to common...
-$2,030,765
Net loss
-$1,980,398
Series b convertible
preferred stock 8...
-$50,367
Interest income
$4,430
Loss from operations
-$1,801,354
Unrealized gain (loss) on
digital assets
-$182,887
Interest expense
$457
Realized gain (loss) on
foreign currency...
-$130
Total costs and
expenses
$1,801,354
General and
administrative costs
$1,750,658
Research and development
costs
$50,696
Buy us a coffee
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)